English
简体中文
繁體中文
客服热线:400-1616-289
登录
注册
会议论文
Updated results from ALTER-C001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC.
Yan, Jin; Han, Yunwei; Zhang, Li; Jin, Yongdong; Sun, Hao
电子科技大学; 重庆大学
Genitourinary Cancers Symposium
2023-2-1
6
阅读
引用
收藏
分享
相关
加载中…
文献加载失败,请重试
重试